Siegfried Grafton Eyes Importing GHB and Weed Extracts
Published Date: 3/19/2026
Notice
Summary
Siegfried Grafton, Inc. wants to become an official importer of certain controlled substances, including Gamma Hydroxybutyric Acid and Marijuana Extract. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 20, 2026. This move could impact how these substances enter the U.S. and might affect businesses handling them.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Import Authorization Limited to Testing/Distribution
The applicant stated it plans to import the listed controlled substances for analytical testing or distribution only; no other activities for these drug codes are authorized for this registration. Authorization will not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale, and approvals will only be issued consistent with 21 U.S.C. 952(a)(2).
Importer Application for Schedule I Drugs
On February 25, 2026, Siegfried Grafton, Inc. applied to be registered as an importer of these Schedule I controlled substances: Gamma Hydroxybutyric Acid (code 2010), Marihuana Extract (7350), Marihuana (7360), 3,4-Methylenedioxy-xymethamphetamine (7405), and Dimethyltryptamine (7435). The application is for importation only and was submitted for review by the Drug Enforcement Administration.
Public Comment and Hearing Deadline
Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before April 20, 2026 (submit comments via https://www.regulations.gov). Hearing requests must also be mailed to DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2026-05355, Importer of Controlled Substances Application: Patheon API Services, Inc.
Patheon API Services, Inc. wants to become an official importer of certain controlled substances like dimethyltryptamine and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 20, 2026. This move could impact companies handling these substances and might affect how these drugs enter the U.S. market.
Next: 2026-05357, Bulk Manufacturer of Controlled Substances Application: Sterling Wisconsin, LLC
Sterling Wisconsin, LLC wants to become a big-time maker of certain controlled substances, including some strong medicines and psychedelics. People and companies who might be affected can share their thoughts or ask for a hearing by May 18, 2026. This move could shake up how these substances are made and handled, but no costs or changes to the public are expected right now.